Association between FIASMA psychotropic medications and reduced risk of intubation or death in individuals with psychiatric disorders hospitalized for severe COVID-19: an observational multicenter study.
Journal
Translational psychiatry
ISSN: 2158-3188
Titre abrégé: Transl Psychiatry
Pays: United States
ID NLM: 101562664
Informations de publication
Date de publication:
03 03 2022
03 03 2022
Historique:
received:
25
02
2021
accepted:
13
01
2022
revised:
07
01
2022
entrez:
4
3
2022
pubmed:
5
3
2022
medline:
11
3
2022
Statut:
epublish
Résumé
The acid sphingomyelinase (ASM)/ceramide system may provide a useful framework for better understanding SARS-CoV-2 infection and the repurposing of psychotropic medications functionally inhibiting the acid sphingomyelinase/ceramide system (named FIASMA psychotropic medications) against COVID-19. We examined the potential usefulness of FIASMA psychotropic medications in patients with psychiatric disorders hospitalized for severe COVID-19, in an observational multicenter study conducted at Greater Paris University hospitals. Of 545 adult inpatients, 164 (30.1%) received a FIASMA psychotropic medication upon hospital admission for COVID-19. We compared the composite endpoint of intubation or death between patients who received a psychotropic FIASMA medication at baseline and those who did not in time-to-event analyses adjusted for sociodemographic characteristics, psychiatric and other medical comorbidity, and other medications. FIASMA psychotropic medication use at baseline was significantly associated with reduced risk of intubation or death in both crude (HR = 0.42; 95%CI = 0.31-0.57; p < 0.01) and primary inverse probability weighting (IPW) (HR = 0.50; 95%CI = 0.37-0.67; p < 0.01) analyses. This association was not specific to one FIASMA psychotropic class or medication. Patients taking a FIASMA antidepressant at baseline had a significantly reduced risk of intubation or death compared with those taking a non-FIASMA antidepressant at baseline in both crude (HR = 0.57; 95%CI = 0.38-0.86; p < 0.01) and primary IPW (HR = 0.57; 95%CI = 0.37-0.87; p < 0.01) analyses. These associations remained significant in multiple sensitivity analyses. Our results show the potential importance of the ASM/ceramide system framework in COVID-19 and support the continuation of FIASMA psychotropic medications in these patients and the need of large- scale clinical trials evaluating FIASMA medications, and particularly FIASMA antidepressants, against COVID-19.
Identifiants
pubmed: 35241663
doi: 10.1038/s41398-022-01804-5
pii: 10.1038/s41398-022-01804-5
pmc: PMC8892828
doi:
Substances chimiques
Psychotropic Drugs
0
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
90Informations de copyright
© 2022. The Author(s).
Références
PLoS One. 2021 Feb 19;16(2):e0247122
pubmed: 33606790
Clin Drug Investig. 2021 Mar;41(3):221-233
pubmed: 33559821
Addiction. 2011 Oct;106(10):1871-2
pubmed: 21917042
Br J Clin Pharmacol. 2021 Oct;87(10):3766-3775
pubmed: 33608891
J Infect. 2020 Jun;80(6):607-613
pubmed: 32283152
Pulm Pharmacol Ther. 2021 Apr;67:101989
pubmed: 33465426
Sci Rep. 2021 Oct 21;11(1):20866
pubmed: 34675292
Sci Rep. 2021 Mar 15;11(1):5890
pubmed: 33723270
Open Forum Infect Dis. 2021 Feb 01;8(2):ofab050
pubmed: 33623808
JAMA. 2020 Dec 8;324(22):2292-2300
pubmed: 33180097
JAMA Intern Med. 2022 Jan 1;182(1):19-25
pubmed: 34747982
Int J Antimicrob Agents. 2020 May;55(5):105954
pubmed: 32234467
JAMA Netw Open. 2021 Nov 1;4(11):e2133090
pubmed: 34779847
J Med Virol. 2020 Oct;92(10):1733-1734
pubmed: 32242950
Mol Neurobiol. 2018 May;55(5):4195-4206
pubmed: 28612257
Dokl Biochem Biophys. 2019 May;484(1):63-65
pubmed: 31012016
PLoS One. 2011;6(8):e23852
pubmed: 21909365
J Pharmacol Sci. 2015 Jan;127(1):6-9
pubmed: 25704012
Lancet Psychiatry. 2021 Sep;8(9):797-812
pubmed: 34274033
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Soc Psychiatry Psychiatr Epidemiol. 2021 Aug;56(8):1411-1425
pubmed: 32415431
Respir Res. 2007 May 03;8:35
pubmed: 17477857
Cell Physiol Biochem. 2010;26(1):9-20
pubmed: 20502000
Lancet. 2009 Jan 3;373(9657):31-41
pubmed: 19058842
Cell Rep Med. 2020 Nov 17;1(8):100142
pubmed: 33163980
FEBS Lett. 2004 Feb 13;559(1-3):96-8
pubmed: 14960314
J Biol Chem. 2021 Jan-Jun;296:100701
pubmed: 33895135
Nat Med. 2020 Sep;26(9):1417-1421
pubmed: 32665655
Pharmaceuticals (Basel). 2021 Mar 07;14(3):
pubmed: 33799977
Microorganisms. 2021 Feb 09;9(2):
pubmed: 33572117
Br J Clin Pharmacol. 2021 Nov 1;:
pubmed: 34719789
Biol Psychiatry. 2007 Oct 15;62(8):878-83
pubmed: 17662961
Acta Psychiatr Scand. 2021 Jun;143(6):526-534
pubmed: 33792912
Mol Psychiatry. 2021 Dec;26(12):7098-7099
pubmed: 34385600
Mol Psychiatry. 2021 Jan;26(1):30-39
pubmed: 32929211
Emerg Microbes Infect. 2020 Dec;9(1):2245-2255
pubmed: 32975484
Front Pharmacol. 2021 Apr 20;12:652688
pubmed: 33959018
Cell Discov. 2020 Mar 16;6:14
pubmed: 32194980
Sci Transl Med. 2019 Feb 6;11(478):
pubmed: 30728287
Int J Mol Sci. 2021 Apr 30;22(9):
pubmed: 33946479
Br J Pharmacol. 2021 Jun;178(11):2339-2350
pubmed: 33825201
Eur J Pharmacol. 2014 Mar 15;727:167-73
pubmed: 24508523
JAMA Netw Open. 2021 Nov 1;4(11):e2136510
pubmed: 34779851
Ideggyogy Sz. 2021 Nov 30;74(11-12):389-396
pubmed: 34856085
Mol Psychiatry. 2021 Sep;26(9):5199-5212
pubmed: 33536545
Clin Pharmacol Ther. 2021 Dec;110(6):1498-1511
pubmed: 34050932
Am J Psychiatry. 2022 Jan;179(1):71-73
pubmed: 34974753
Mol Psychiatry. 2021 Oct 4;:
pubmed: 34608263
Encephale. 2020 Jun;46(3):193-201
pubmed: 32370982
N Engl J Med. 2020 Jun 18;382(25):2411-2418
pubmed: 32379955
Mol Psychiatry. 2021 Nov 26;:
pubmed: 34837060
J Clin Med. 2021 Dec 15;10(24):
pubmed: 34945186
Epidemiology. 2000 Sep;11(5):550-60
pubmed: 10955408
J Travel Med. 2021 Feb 23;28(2):
pubmed: 33506243
Front Pharmacol. 2020 Nov 09;11:582310
pubmed: 33364957
Inflamm Regen. 2020 Oct 1;40:37
pubmed: 33014208
Biomed Pharmacother. 2021 Jun;138:111437
pubmed: 33691249
Lancet. 2019 Sep 14;394(10202):939-951
pubmed: 31303314
BJPsych Open. 2021 Dec 03;8(1):e6
pubmed: 34859759
Focus (Am Psychiatr Publ). 2018 Oct;16(4):420-429
pubmed: 32021580
JAMA Netw Open. 2020 Sep 1;3(9):e2023282
pubmed: 32997123
Int J Mol Sci. 2021 Sep 22;22(19):
pubmed: 34638539
Lancet Glob Health. 2022 Jan;10(1):e42-e51
pubmed: 34717820
Front Pharmacol. 2022 Jan 19;12:755600
pubmed: 35126106
Nat Med. 2013 Jul;19(7):934-8
pubmed: 23770692
Biol Psychiatry Glob Open Sci. 2022 Jan 4;:
pubmed: 35013734
Biol Chem Hoppe Seyler. 1994 Jul;375(7):447-50
pubmed: 7945993